Patent application number | Description | Published |
20110085979 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS - Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. | 04-14-2011 |
20110142764 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES - Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. | 06-16-2011 |
20110286923 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES - Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed. | 11-24-2011 |
20140010763 | ACTIVATABLE FLUOROGENIC COMPOUNDS AND USES THEREOF AS NEAR INFRARED PROBES - Novel fluorogenic compounds designed such that upon a chemical event, compounds capable of emitting NIR light are generated, are disclosed. The compounds comprise two or more acceptor-containing moieties and a cleavable donor-containing moiety, being in complete pi-electrons conjugation and being such that no delocalization of pi-electrons is enabled. Also disclosed are fluorescent compounds generated upon subjecting the fluorogenic compounds to a chemical event (e.g., deprotonation). Also disclosed are uses of the fluorogenic compounds as NIR probed with a Turn-ON mechanism in monitoring presence and/or level of various analytes. | 01-09-2014 |
20140079638 | NOVEL CONJUGATES OF POLYMERS HAVING A THERAPEUTICALLY ACTIVE AGENT AND AN ANGIOGENESIS TARGETING MOIETY ATTACHED THERETO AND USES THEREOF IN THE TREATMENT OF ANGIOGENESIS RELATED DISEASES - Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed. | 03-20-2014 |
20140134111 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES - Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. | 05-15-2014 |
20140212357 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS - Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. | 07-31-2014 |
20140271483 | TARGETED POLYMERIC CONJUGATES AND USES THEREOF - Polymeric conjugates comprising a polymeric backbone having attached thereto a bone targeting moiety and a therapeutically active agent, wherein the bone targeting moiety is attached to one end of the polymeric backbone via a branching unit such that a molar ratio of the bone targeting moiety to the polymer is at least 2:1, are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of bone related disorders are also disclosed. | 09-18-2014 |
20150017115 | POLYMERS HAVING THERAPEUTICALLY ACTIVE AGENTS CONJUGATED THERETO, PROCESSES OF PREPARING SAME AND USES THEREOF - Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed. | 01-15-2015 |